Skip to main content

Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks

Completed · Phase 3 · NCT04739059

Conditions: Hereditary Angioedema

At a glance

Research payments reported, 2025
$233,422
U.S. investigators named
9
Sites paid
9
Planned or actual enrollment
171

About the trial

Sponsor
CSL Behring
Tested
CSL312 (biological)
Dates
Started 2021-03-29; completion 2025-11-21
Results posted
Yes

This phase 3b study will evaluate long-term safety and efficacy of CSL312 (also known as garadacimab) when administered subcutaneously (SC)

From ClinicalTrials.gov, last updated 2026-06-02. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Csl Behring reported $233,422 in research payments for this study in 2025 (111 payments).

Products named: Berinert, Andembry

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Allergy and Asthma Clinical Research $102,632
  • $27,456
  • Research Solutions of Arizona (dcrpi) $26,535
  • Bernstein Clinical Research Center $24,950
  • Penn State State College of Medicine $18,660
  • Institute for Asthma and Allergy $17,391
  • Clinical Research Center of Alabama Homewood Office $12,012
  • Acuro Research Inc $2,829
  • Aara Research Center $695
  • Allergy Asthma and Immunology Associates South Scottsdale Office $261

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.